Oryzon Genomics
Oryzon Genomics
ORY
BME
2.84
EUR
-0.70%
About
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses.
The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 40.8K |
| Three Month Average Volume | 1.9M |
| High Low | |
| Fifty-Two Week High | 2.385 EUR |
| Fifty-Two Week Low | 1.552 EUR |
| Fifty-Two Week High Date | 08 Jan 2024 |
| Fifty-Two Week Low Date | 07 Mar 2024 |
| Price and Volume | |
| Current Price | 1.782 EUR |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -7.02% |
| Thirteen Week Relative Price Change | -11.08% |
| Twenty-Six Week Relative Price Change | -10.11% |
| Fifty-Two Week Relative Price Change | -28.74% |
| Year-to-Date Relative Price Change | -16.37% |
| Price Change | |
| One Day Price Change | 0.56% |
| Thirteen Week Price Change | -10.45% |
| Twenty-Six Week Price Change | 1.83% |
| Five Day Price Change | 0.91% |
| Fifty-Two Week Price Change | -14.53% |
| Year-to-Date Price Change | -5.61% |
| Month-to-Date Price Change | -4.30% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.34323 EUR |
| Book Value Per Share (Most Recent Quarter) | 1.37451 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.13339 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.1184 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.06818 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 EUR |
| Revenue Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | -99999.99 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.05508 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.05965 EUR |
| Normalized (Last Fiscal Year) | -0.05508 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.05508 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.05965 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -0.05508 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -0.05965 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.20133 EUR |
| Cash Per Share (Most Recent Quarter) | 0.16009 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -0.05256 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -0.05783 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -99999.99 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 2.74% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 15.52% |
| Total Debt (5 Year) | -1.59% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -90.91% |
| EPS Change (Trailing Twelve Months) | -0.96% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 3.3M |
| Net Debt (Last Fiscal Year) | 1.4M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 4 |
| Long Term Debt to Equity (Most Recent Quarter) | 4 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -15,077,560 |
| Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -3 |
| Net Interest Coverage (Trailing Twelve Months) | -4 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 17 |
| Total Debt to Equity (Most Recent Quarter) | 15 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -3.18% |
| Return on Assets (Trailing Twelve Months) | -3.55% |
| Return on Assets (5 Year) | -4.20% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -4.34% |
| Return on Equity (Trailing Twelve Months) | -4.63% |
| Return on Equity (5 Year) | -5.62% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -3.82% |
| Return on Investment (Trailing Twelve Months) | -4.13% |
| Return on Investment (5 Year) | -4.82% |